Insulin exposed endometrial epithelial cells cultured in a microfluidic device alters transcripts involved in translation that may contribute to reduced implantation capacity of the endometrium.

Soo Young Baik¹, Haidee Tinning¹, Dapeng Wang^{2,3}, Niamh Forde^{1*}

¹Discovery and Translational Sciences Department, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, LS2 9JT, United Kingdom.

²LeedsOmics, University of Leeds, Leeds, LS2 9JT, United Kingdom.

³Wellcome Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, United Kingdom

* Correspondence should be addressed to n.forde@leeds.ac.uk

ABSTRACT

Obesity is a rapidly growing public health issue among women of reproductive age. It is also associated with decreased reproductive function including implantation failure. Implantation failure can result from a myriad of factors including impaired gametes and endometrial dysfunction. The mechanisms of how obesity-related hyperinsulinaemia disrupts endometrial function and implantation are poorly understood. Our study aims to investigate potential mechanisms by which insulin alters endometrial transcript expression, which may affect endometrial receptivity. Ishikawa cells mimicking human endometrial epithelium were seeded into a microfluidics organ-on-chip device to produce an *in vitro* endometrium. Syringe pump was attached to the microfluidics device to deliver three varying treatments into Ishikawa cells: 1) media control 2) vehicle control (PBS acidified to pH3 with acetic acid) 3) Insulin (2mg/mL) at a constant flow rate of 1uL/min for 24 hours to mimic secretion *in vivo*. Three biological replicates were obtained. Insulin-induced transcriptomic response of the *in vitro* endometrium was quantified via RNA sequencing, and subsequently analysed using DAVID and Webgestalt to identify Gene Ontology (GO) terms and signalling pathways. A Total of 29 transcripts showed differential expression levels across two comparison groups (control v vehicle control; vehicle control v insulin). There were nine transcripts significantly differentially expressed in vehicle control v insulin group ($p < 0.05$). Functional annotation analysis of transcripts altered by insulin ($n=9$) identified three significantly enriched GO terms: SRP-dependent cotranslational protein targeting to membrane, poly(A) binding, and RNA binding ($p < 0.05$). Over-representation analysis found three significantly enriched signalling pathways relating to insulin-induced transcriptomic response: protein export, glutathione metabolism, and ribosome pathways ($p < 0.05$). Insulin-induced dysregulation of biological functions and pathways highlight potential mechanisms by which high insulin concentrations within maternal circulation may perturb endometrial receptivity.

INTRODUCTION

Obesity is a complex disease with multifactorial aetiologies and in the UK, almost half of women within the childbearing age range are overweight or obese. Due to complex biochemical changes in the endocrinological and metabolic profile of those suffering from obesity, there are resulting complex health issues including insulin resistance and compensatory hyperinsulinaemia [1]. This has been linked to poor reproductive outcomes in women of childbearing age such as miscarriage, anovulation, irregular menstrual cycles, decreased conception rates in ART [2, 3].

The impact of obesity on ovarian function dysregulation is well recognised although complex. The higher concentrations of insulin in circulation associated with obesity can inhibit sex hormone binding globulin (SHBG) production by the liver [4] along with aromatisation of androgens to oestrogens associated with increased adipose tissue. As SHBG binds to circulating sex hormones; the combined effects of high peripheral aromatisation of androgens and decreased SHBG leads to an overall increase in bioavailable oestradiol and testosterone, therefore contributing to hyperandrogenism in the theca cells of the ovarian follicles [1] [2]. Hyperinsulinaemia and subsequent hyperandrogenism coupled with altered hormonal milieu can lead to premature follicular atresia and anovulation [2]. Furthermore, increased insulin in circulation associated with obesity can lead to inhibition of hepatic and ovarian IGF binding protein 1 (IGFBP1) expression an important regulator of ovarian and endometrial function. Overall, the combined effects of systemic insulin resistance and hyperinsulinaemia in obesity contribute to biochemical and sex hormone dysregulation within the female reproductive system. Such symptoms common features of polycystic ovarian syndrome (PCOS), and obesity related hyperinsulinaemia seems to exacerbate PCOS symptoms [5].

The effects that this dysregulation in metabolic and biochemical profiles associated with obesity have on endometrial function and uterine receptivity remains unclear. Conflicting results and discrepancies in methodologies between the studies may explain in part why this is the case. A series of studies from ovum donation cycles identified significantly higher spontaneous abortion rates in obese women (38.1%) compared to women with normal BMI (13.3%) [6], with a follow up study of 2656 first ovum donation cycles concluded that high BMI altered endometrial environment and function, although these effects are quite small [7]. A further investigation into 9,587 first cycle ovum donations showed that implantation, clinical pregnancy, and live-birth rates were significantly reduced in obese

women, although miscarriage rates showed no difference with BMI [8] similar to what was observed by Cano et al, [9]. In contrast, no significant differences in receptivity impairment between obese and non-obese women were observed [10] or implantation rate or miscarriage rate in high BMI groups compared to lower BMI [11] although in this study miscarriage rates that were disproportionately high.

The studies critiqued above illustrate the controversial nature of the effect of obesity on endometrial function/implantation using the ovum donation model to isolate the impact of endometrial factors from the embryonic influence in implantation capability. This model limits study participants only to those participating in oocyte donation to remove the influence of poor embryo quality on implantation failure. Given there are likely fundamental differences in those that require ovum donation in obese and non-obese scenarios these are likely to. Compound results [12, 13]. Overall, these clinical studies highlight the gap in knowledge in regard to the mechanism by which the metabolic and biochemical changes in circulation contributes to dysfunction in endometrial function and receptivity.

Glucose metabolism is important during the peri-implantation window with expression of the facilitative glucose transporters (GLUT) in endometrial epithelia modulated by oestradiol and progesterone [14]. Furthermore, upregulation of glucose and its transporter (*GLUT1*) are critical for endometrial stromal cell decidualisation [15]. Obesity-related insulin resistance and hyperinsulinaemia leads to disturbances in glucose metabolism, which may have downstream effects on endometrial function and receptivity [16]. Dissecting out the complex interactions between insulin-specific alterations on endometrial function without the confounding influence of additional metabolic stressors in circulation it difficult. Moreover, static culture systems *in vitro* do not recapitulate exposure *in vivo*. Evidence in other species looking at the proteomic analysis on endometria of sows with normal reproductive performance and low reproductive performance to pinpoint the differentially expressed genes and pathways (ie. Insulin-signalling pathway and lipid metabolism) associated with uterine impairment. Chen et al. subsequently used insulin-resistant animal models driven by high-fat diet and Ishikawa cells (human endometrial adenocarcinoma cells) to create *in vitro* implantation models and reported that insulin resistance reduces receptivity through mitochondrial dysfunction and consequent oxidative stress [17]. Additionally, the use of a microfluidics endometrium-on-a-chip in bovine demonstrated cellular transcriptional and

secretome differences if the endometrium following exposure to physiological extremes of metabolic factors glucose and insulin in microfluidics [18].

However, both models used animal endometrial tissue, and these findings can only be applied to humans to some extent. Various research investigating whether obesity impairs endometrial receptivity reveals conflicting findings; they also lack validity due to methodological limitations and complications associated with using the ovum-donation model. There is an overall scarcity in literature highlighting hyperinsulinaemia in obesity as an aetiology of poor uterine function and implantation. We therefore propose to investigate the impact of obesity-related metabolic stressor of insulin on endometrial function. To achieve this, we used a microfluidics approach to better mimic *in vitro*, exposure of the endometrial epithelium to Insulin that would occur *in vivo*. This allowed us to identify the transcriptional response of the endometrial epithelium revealing potential mechanism by which hyperinsulinaemia in obesity may contribute to endometrial dysfunction.

MATERIALS AND METHODS

Unless otherwise stated all consumables were sourced from Sigma Aldrich (UK).

Culture of Ishikawa cells and device preparation

Passage 20-24 Ishikawa cells (Immortalised human endometrial cells; ECACC #99040201) cultured in DMEM/F-12 [Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12], containing 10% FBS [foetal bovine serum], 1% GSP [glutamine, streptomycin, penicillin]) were trypsinised from a T75 flask and counted using a hemacytometer. Media (described above) was added to cells until they reached a concentration of 1,000,000/mL. The microfluidics device (Ibidi u-slide V0.4) were placed in the incubator at 37°C. One hundred microlitres of the of 1,000,000/mL Ishikawa cell suspension was subsequently seeded into each channel of V0.4 slides, and left to attach for 12 hr. Media (DMEM/F12, 10% FBS, 1% GSP) was added to each channel until almost full to prevent channel from drying. Ishikawa cells were left for 24 hr in 37°C incubator with 5% CO₂ before undergoing treatment in the microfluidics device.

Treatment of Ishikawa cells with Insulin in a microfluidic device

Each channel of the microfluidics device was flushed five times with 37°C PBS and the inlet syringes were connected with sterile tubing. Elbow connectors were then used to attach the sterile tubing the microfluidics device inlet. Sterile tubing was filled with medium from the syringes and attached to the device. A droplet to droplet method was used to prevent introduction of bubbles into the device. Syringes were pushed to fill both the chamber and outlet. The outlet tubing was filled with sterile PBS and connected to the outlets on microfluidics channels using the droplet-droplet method. The other end of each outlet tube was connected to a 7mL bijou container to collect and save the conditioned medium. After setting up the microfluidics device, medium was pushed through the entire device system to check for bubbles, and to get a droplet at the end of each outlet tube inside the bijou container. The microfluidics device set-up can be pictured in Figure 1.

Cells within the devices were exposed to one of following three treatments for 24 hr (n=3 biological replicates): 1) media control, 2) vehicle control (PBS [phosphate-buffered saline] acidified to pH3 with acetic acid [A6283]), and 3) Insulin (2 mg/ml in PBS acidified to pH3 with acetic acid). Each treatment was loaded into a 5mL syringe and put in 37°C incubator overnight and loaded onto the syringe pump on the day of microfluidics run. The syringe pump and microfluidics system were placed into a 37°C incubator and the syringe pump was set to flow at the rate of 1µL/min in order to mimic secretion *in vivo* (as previously described; [18]).

Cell Recovery and RNA extraction and RNA sequencing

After disconnecting the microfluidics device from the system, every channel from the device was flushed with PBS. Ishikawa cells were lifted with trypsin, neutralised with media, and centrifuged at 500g for 5 min to pellet the cells. The resulting cell pellet was then snap frozen in liquid nitrogen until RNA extraction. RNA extraction was carried by using the Mini RNeasy Kit (Qiagen), according to instructions provided by manufacturer. Extracted RNA was sent to Novogene (Cambridge, UK) for subsequent library preparation. Ribosomal RNA was firstly removed and a directional sequencing library was constructed using NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB, USA) following manufacturer's protocol. Indices were included to multiplex multiple samples. Briefly, the first strand cDNA was synthesized using random hexamer primers followed by the second strand cDNA synthesis. The strand-specific library was ready after

end repair, A-tailing, adapter ligation, size selection, and USER enzyme digestion. After amplification and purification, insert size of the library was validated on an Agilent 2100 and quantified using quantitative PCR (Q-PCR). Libraries were then sequenced on Illumina NovaSeq 6000 S4 flowcell with PE150 according to results from library quality control and expected data volume.

Bioinformatic analysis

The raw and processed FASTQ files were scanned for the fundamental quality control metrics using FastQC (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). The adapter sequences in the reads were trimmed off using Cutadapt [19] and poor quality bases or reads were trimmed or discarded using PRINSEQ [20]. The human reference genome file (GRCh38) and corresponding GTF file were downloaded from GENCODE Human Release 31 [21]. The processed paired-end reads were aligned onto the human reference genome using STAR [22]. The resultant alignment files were converted, sorted and indexed with SAMtools [23] and only uniquely mapped reads were selected for the downstream analysis. The reads were counted for each gene using featureCounts() function of Rsubread package and a matrix of raw read counts for all genes was produced [24]. The differential expression testing was performed using DESeq2 with apegglm method for the log₂ fold change shrinkage > 0.1 (or < -0.1) and p value of < 0.05 [25].

Differentially expressed protein-coding genes found in three treatment groups were subjected to Gene Ontology (GO) functional annotations and over-representation enrichment analysis using DAVID (The Database for Annotation, Visualization and Integrated Discovery; Bioinformatics Resourced 6.8 [26]) and WebGestalt (WEB-based Gene SeT Analysis Toolkit [27]), respectively. Gene identifier for DAVID was chosen as “OFFICIAL_GENE_SYMBOL,” with list type selected as “Gene List.” When using WebGestalt, the functional database was chosen as “KEGG Pathway,” and gene ID type was “Gene symbol.” Gene reference set when using WebGestalt was “genome protein-coding.” P-value cutoff was p<0.05. P-values for both DAVID and WebGestalt were adjusted as FDR using the Benjamini-Hochberg Method, with the statistical significance threshold set as FDR<0.05. GO functional annotation terms was presented by their Enrichment scores, calculated by $-\log_{10}^{[Pvalue]}$, and over-representation analysis on WebGestalt was displayed by presenting each signalling pathways’ enrichment ratios and FDR.

RESULTS

Acidified PBS used as a vehicle alters the transcriptome of endometrial epithelial cells exposed in a microfluidic device

Differentially expressed genes (DEGs) from each of the three treatment groups (control, vehicle control [VC], and insulin) were compared with one another to minimise the confounder of VC added in with insulin. Comparison of control to VC altered the expression of 22 transcripts in total (Figure 2: Table 1). Genes involved in the biological processes of Mitochondrial electron transport, NADH to ubiquinone and Mitochondrial respiratory chain complex I assembly were overrepresented in the list of DEGs (Table 2). There were more transcripts associated with the cellular components of Respiratory chain, Mitochondrial inner membrane, Mitochondrial respiratory chain complex I, and Mitochondrion as well as the molecular functions of NADH dehydrogenase (ubiquinone) activity and Cytochrome-c oxidase activity, than one would have expected by chance (For full details see Table 2). While there were a number of overrepresented pathways (including those associated with thiamine metabolism, and folate biosynthesis) none had an FDR of <0.05 (Figure 3: Table 3).

Exposure of endometrial epithelial cells to Insulin in a microfluidics device altered the transcriptional profile.

Exposure of Ishikawa cells to Insulin altered the expression of 9 genes (Figure 2: Table 1). Two of these transcripts were altered in both comparisons however, *TSMB10* and *RPS6* were increased in expression in control versus VC but were significantly decreased in VC compared to insulin treated cells. The molecular function of Poly(A) RNA binding was significantly overrepresented in cells exposed to insulin in a microfluidic device (Figure 4: Table 4). While genes associated with the pathways Protein export, Glutathione metabolism, and Ribosome (Table 5) were significantly overrepresented following insulin exposure. Comparisons of the overrepresented biological processes, cellular components, and molecular functions are provided in Figure 5.

DISCUSSION

To the best of our knowledge, our study is the first to use a microfluidics approach to mimic exposure of the endometrial epithelium to obesogenic concentrations of insulin

associated with maternal circulation to enhance our understanding of the mechanism by which endometrial function may be affected obesity. This was conducted by allowing exposure of Ishikawa cells in a microfluidics device to insulin concentration associated with an obese environment and identifying the associated pathways and functional annotations that were modified. Our results indicate that maternal metabolic stressors, insulin, may alter uterine function and receptivity by altering specific transcripts in the endometrial epithelium and propose the mechanisms by which this may occur (Figure 7).

The vehicle control used to deliver Insulin to the cells altered biological functions of mitochondrial electron transport (NADH to ubiquinone), mitochondrial respiratory chain complex I assembly, ATP synthesis; molecular functions of NADH dehydrogenase (ubiquinone activity), and cytochrome-c oxidase activity were altered. While NADH dehydrogenase promotes the smooth functioning of respiration and ATP synthesis by stimulating the assembly of respiratory chain complex I, they may have an additional role of producing apoptosis-inducing fragments to promote cell death [28, 29]. This alternative role of NADH dehydrogenase in our findings with VC can be further substantiated by the fact acetic acid is reported to induce apoptosis in a gastric cell line [30]. Apoptosis in cells is initiated by acetic acid by mitochondrial dysfunction, cytochrome-c release, and along with reactive oxygen species accumulation, which seem to correlate with the GO terms found in control v VC [31]. Using acetic acid might have stimulated mitochondria-induced apoptosis in the Ishikawa cells.

The processes and signalling pathways modified by insulin treatment may provide a major insight into the function of insulin endometrial receptivity specifically those related to processes involving translation. Translation initiation, is facilitated by binding of ribosomes to the 5'cap of mRNAs and is mediated by the eukaryotic translation initiation factor 4F (eIF4F) complex. One of the major components of the eIF4F complex is the eIF4G, which aids in recruiting and binding of the ribosome. The 3' poly(A) tail end of the mRNA binds to the poly(A) binding protein (PABP) with PABP and eIF4G interaction synergistically initiates translation [32, 33]. The mTOR signalling pathway was also shown to be modified by insulin in our study and this signalling pathway is implicated in translational initiation by phosphorylating translation factors such as EIF4E binding protein [34]. Furthermore, *RPS6* phosphorylation (a DEG significantly downregulated by insulin in our findings) within the mTOR pathway is widely accepted to stimulate protein synthesis and translation [35]; cellular protein synthesis capacity is widened by the mTOR pathway and is critical to cell survival [36].

Translation modulation, and increased ribosome synthesis are implicated in endometrial epithelial cell function and receptivity given the dynamic nature of the human endometrium [32, 37]. A recent study identified the proteins involved in repeated implantation failure revealed were involved in translation pathways, posttranslational modification and ribosomal pathways were heavily enriched in the differentially expressed proteins [38]. It is thus clear that our findings show evidence that insulin treatment potentially modifies the translational profile of endometrial epithelial cells.

Insulin treatment induced differential expression of transcripts from Ishikawa cells, which may provide insight into how obesity-related insulin changes can alter endometrial function. *RPS6* (Ribosomal protein S6) is a transcript that is associated with many of the enriched and over-represented pathways in analysis. The gene is highly expressed in the endometrium, with 1752 Transcripts per million expressed in the endometrial tissue [39]. Aside from its role in translation regulation in the ribosomal and mTOR pathway, it is also implicated in immune response regulation [39]. Phosphorylation of *RPS6* is necessary for T-cell differentiation in the thymus [40], plays a key role in the mTOR pathway, which has been demonstrated to be involved in T-cell signalling [41]. The immune profile of the endometrium plays a critical role in implantation success via T-cell mediated immune toleration [42]. In fact, research showed that patients experiencing RIF during IVF had a dysregulated endometrial uterine immune profile [43]. Taking into consideration of the well-documented responsibility of *RPS6* in regulating T cell expression during the immune response, and that insulin downregulated *RPS6* expression, it can be hypothesised that high circulating insulin in the endometrium may compromise the uterine immune profile and consequent receptivity.

GGCT encodes an enzymatic protein essential for glutathione metabolism. Dysregulation in the glutathione metabolism pathway is associated with insulin resistance, hyperinsulinaemia, and type 2 diabetes [44, 45]. It is thought that *GGCT* is important in cellular protective mechanisms by salvaging glutathione, thereby providing an antioxidant effect to cells [46]. Glutathione is a critical modulator of normal cellular function such as gene expression, protein synthesis, and immune response but is primarily involved in antioxidative roles and nutrient metabolism [47]. Glutathione deficiency leads to accumulation of free-radicals and oxidative stress [48]. Glutathione metabolism also may play a major role in fertility and endometrial function, as Xu et al. [49] demonstrated that this pathway is crucial in reducing hydrogen peroxide (a type of reactive oxygen species that causes oxidative stress)

during decidualisation. High concentrations of reactive oxygen species (ROS) and oxidative stress adversely affects implantation process, early embryo development, and can eventually cause implantation failure [50] as well as normal endometrial function, making the environment unsuitable to support growth and development of the embryo [51]. We propose that insulin can disturb glutathione homeostasis in the endometrium, thereby leading to oxidative stress and subsequent effects on uterine receptivity to implantation.

The downregulation of *TMSB10* with insulin treatment encodes a protein that aids the processes of actin filament organization and actin binding [39]. During the window of receptivity, the human endometrial surface goes through ultrastructural modifications which includes the development of pinopodes, which is tightly managed by cytoskeletal actin filaments [52, 53]. Although previously controversial, recent literature has deemed the presence of pinopodes in the endometrial epithelia as a credible biomarker of uterine receptivity [52, 54]. Filamentous actin expression coincides with pinopode formation during receptivity on the apical surface of luminal epithelial cells [55]. In the endometria of from those suffering recurrent pregnancy loss, both ezrin and thrombomodulins were downregulated which disrupted the organisation of cytoskeletal actin filaments and may ultimately impaired pinopode formation. *TMSB10* was differentially expressed and highly responsive to oestradiol and progesterone [56] and has been associated with a functional and receptive endometrium [57]. We conclude that insulin concentrations can downregulate *TMSB10*, which may contribute to impaired implantation capacity of the endometrium.

Despite numerous reports on the potential contribution of insulin as a metabolic stressor in obesity, the mechanism by which uterine receptivity may be compromised is still unknown. Existing literature studying this phenomenon and underlying mechanisms utilised hyperinsulinaemic animal models [17, 58], which may not accurately reflect the inner workings of a human endometria. Our findings aimed to provide insight into this gap in knowledge through using a microfluidics approach. Microfluidics can also simulate shear stress and communications between cells, elucidating that the constant flow of maternal circulation within the endometria can be modelled effectively through the device [59]. In conclusion, our results indicate that insulin alters the transcriptional profile of the endometrial epithelial cells when cultured in a microfluidics device. The biological processes and signalling pathways associated with differentially expressed transcripts found following insulin treatment were related to certain mechanisms of endometrial receptivity and

implantation (Figurer 7). Specifically, genes and processes related translation, immune response regulation, glutathione metabolism, and actin filament organisations seem to be dysregulated with insulin treatment, which may ultimately impair implantation success and reduce pregnancy success in those suffering from obesity.

ACKNOWLEDGEMENTS

NF's lab is supported by funding from N8 agri-food pump priming, QR GCRF, UN-CRP, as well as BBSRC grant number BB/R017522/1. RNA sequencing analysis was undertaken on ARC3, part of the High-Performance Computing facilities at the University of Leeds, UK. Figures 1 and 7 were created using Biorender.

REFERENCES

1. Talmor, A. and B. Dunphy, *Female Obesity and Infertility*. Best Practice & Research Clinical Obstetrics & Gynaecology, 2015. **29**(4): p. 498-506.
2. Pasquali, R., et al., *Obesity and reproductive disorders in women*. Human Reproduction Update, 2003. **9**(4): p. 359-372.
3. Silvestris, E., et al., *Obesity as disruptor of the female fertility*. Reproductive biology and endocrinology : RB&E, 2018. **16**(1): p. 22-22.
4. Daka, B., et al., *Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden*. Endocrine connections, 2012. **2**(1): p. 18-22.
5. Broughton, D.E. and K.H. Moley, *Obesity and female infertility: potential mediators of obesity's impact*. Fertil Steril, 2017. **107**(4): p. 840-847.
6. Bellver, J., et al., *Obesity and the risk of spontaneous abortion after oocyte donation*. Fertility and Sterility, 2003. **79**(5): p. 1136-1140.
7. Bellver, J., et al., *Obesity and poor reproductive outcome: the potential role of the endometrium*. Fertil Steril, 2007. **88**(2): p. 446-51.
8. Bellver, J., et al., *Obesity reduces uterine receptivity: clinical experience from 9,587 first cycles of ovum donation with normal weight donors*. Fertil Steril, 2013. **100**(4): p. 1050-8.
9. Cano, F., et al., *The effect of extreme of body mass on embryo implantation at oocytes donation program*. Fertility and Sterility, 2001. **76**(3): p. S160-S161.
10. Wattanakumtornkul, S., et al., *Body mass index and uterine receptivity in the oocyte donation model*. Fertility and Sterility, 2003. **80**(2): p. 336-340.
11. Styne-Gross, A., K. Elkind-Hirsch, and R.T. Scott, *Obesity does not impact implantation rates or pregnancy outcome in women attempting conception through oocyte donation*. Fertility and Sterility, 2005. **83**(6): p. 1629-1634.
12. Brewer, C.J. and A.H. Balen, *The adverse effects of obesity on conception and implantation*. Reproduction, 2010. **140**(3): p. 347-64.

13. Howards, P.P. and M.A. Cooney, *Disentangling causal paths between obesity and in vitro fertilization outcomes: an intractable problem?* Fertility and Sterility, 2008. **89**(6): p. 1604-1605.
14. Kim, S.T. and K.H. Moley, *Regulation of facilitative glucose transporters and AKT/MAPK/PRKAA signaling via estradiol and progesterone in the mouse uterine epithelium.* Biology of reproduction, 2009. **81**(1): p. 188-198.
15. Schulte, M.M.B., J.-h. Tsai, and K.H. Moley, *Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation.* Reproductive sciences (Thousand Oaks, Calif.), 2015. **22**(1): p. 6-14.
16. Shanik, M.H., et al., *Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?* Diabetes Care, 2008. **31 Suppl 2**: p. S262-8.
17. Chen, M., et al., *Uterine Insulin Sensitivity Defects Induced Embryo Implantation Loss Associated with Mitochondrial Dysfunction-Triggered Oxidative Stress.* Oxid Med Cell Longev, 2021. **2021**: p. 6655685.
18. De Bem, T.H.C., et al., *Endometrium On-a-Chip Reveals Insulin- and Glucose-induced Alterations in the Transcriptome and Proteomic Secretome.* Endocrinology, 2021. **162**(6).
19. Martin, M., *Cutadapt removes adapter sequences from high-throughput sequencing reads.* 2011, 2011. **17**(1): p. 3.
20. Schmieder, R. and R. Edwards, *Quality control and preprocessing of metagenomic datasets.* Bioinformatics (Oxford, England), 2011. **27**(6): p. 863-864.
21. Frankish, A., et al., *GENCODE reference annotation for the human and mouse genomes.* Nucleic acids research, 2019. **47**(D1): p. D766-D773.
22. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner.* Bioinformatics (Oxford, England), 2013. **29**(1): p. 15-21.
23. Li, H., et al., *The Sequence Alignment/Map format and SAMtools.* Bioinformatics (Oxford, England), 2009. **25**(16): p. 2078-2079.
24. Liao, Y., G.K. Smyth, and W. Shi, *The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads.* Nucleic acids research, 2019. **47**(8): p. e47-e47.
25. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.* Genome biology, 2014. **15**(12): p. 550-550.
26. Huang, D.W., B.T. Sherman, and R.A. Lempicki, *Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.* Nature Protocols, 2009. **4**(1): p. 44-57.
27. Liao, Y., et al., *WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs.* Nucleic acids research, 2019. **47**(W1): p. W199-W205.
28. Saladi, S., et al., *The NADH Dehydrogenase Nde1 Executes Cell Death after Integrating Signals from Metabolism and Proteostasis on the Mitochondrial Surface.* Molecular Cell, 2020. **77**(1): p. 189-202.e6.
29. Herrmann, J.M. and J. Riemer, *Apoptosis inducing factor and mitochondrial NADH dehydrogenases: redox-controlled gear boxes to switch between mitochondrial biogenesis and cell death.* Biol Chem, 2021. **402**(3): p. 289-297.
30. Okabe, S., et al., *Acetic acid induces cell death: an in vitro study using normal rat gastric mucosal cell line and rat and human gastric cancer and mesothelioma cell lines.* J Gastroenterol Hepatol, 2014. **29 Suppl 4**: p. 65-9.

31. Marques, C., et al., *Acetate-induced apoptosis in colorectal carcinoma cells involves lysosomal membrane permeabilization and cathepsin D release*. Cell death & disease, 2013. **4**(2): p. e507-e507.
32. Berlanga, J.J., A. Baass, and N. Sonenberg, *Regulation of poly(A) binding protein function in translation: Characterization of the Paip2 homolog, Paip2B*. RNA (New York, N.Y.), 2006. **12**(8): p. 1556-1568.
33. Prévôt, D., J.L. Darlix, and T. Ohlmann, *Conducting the initiation of protein synthesis: the role of eIF4G*. Biol Cell, 2003. **95**(3-4): p. 141-56.
34. Saxton, R.A. and D.M. Sabatini, *mTOR Signaling in Growth, Metabolism, and Disease*. Cell, 2017. **168**(6): p. 960-976.
35. Mok, K.W., D.D. Mruk, and C.Y. Cheng, *Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2*. International review of cell and molecular biology, 2013. **301**: p. 291-358.
36. Johnson, S.C., P.S. Rabinovitch, and M. Kaeberlein, *mTOR is a key modulator of ageing and age-related disease*. Nature, 2013. **493**(7432): p. 338-345.
37. Wang, Y., et al., *Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17 β is mediated by a PKC-ERK1/2-mTOR signaling pathway*. Proceedings of the National Academy of Sciences of the United States of America, 2015. **112**(11): p. E1382-E1391.
38. Wang, C., et al., *Screening and identification of endometrial proteins as novel potential biomarkers for repeated implantation failure*. PeerJ, 2021. **9**: p. e11009-e11009.
39. Howe, K.L., et al., *Ensembl 2021*. Nucleic Acids Research, 2020. **49**(D1): p. D884-D891.
40. Salmond, R.J., et al., *Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation*. Journal of immunology (Baltimore, Md. : 1950), 2015. **195**(10): p. 4615-4622.
41. Salmond, R.J., et al., *MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells*. J Immunol, 2009. **183**(11): p. 7388-97.
42. Robertson, S.A., A.S. Care, and L.M. Moldenhauer, *Regulatory T cells in embryo implantation and the immune response to pregnancy*. The Journal of clinical investigation, 2018. **128**(10): p. 4224-4235.
43. Lédée, N., et al., *The Uterine Immune Profile May Help Women With Repeated Unexplained Embryo Implantation Failure After In Vitro Fertilization*. American journal of reproductive immunology (New York, N.Y. : 1989), 2016. **75**(3): p. 388-401.
44. Kobayashi, H., et al., *Dysregulated glutathione metabolism links to impaired insulin action in adipocytes*. Am J Physiol Endocrinol Metab, 2009. **296**(6): p. E1326-34.
45. Hakki Kalkan, I. and M. Suher, *The relationship between the level of glutathione, impairment of glucose metabolism and complications of diabetes mellitus*. Pakistan journal of medical sciences, 2013. **29**(4): p. 938-942.
46. Kageyama, S., et al., *Mechanisms of Tumor Growth Inhibition by Depletion of γ -Glutamylcyclotransferase (GGCT): A Novel Molecular Target for Anticancer Therapy*. International journal of molecular sciences, 2018. **19**(7): p. 2054.
47. Wu, G., et al., *Glutathione Metabolism and Its Implications for Health*. The Journal of Nutrition, 2004. **134**(3): p. 489-492.
48. Pham-Huy, L.A., H. He, and C. Pham-Huy, *Free radicals, antioxidants in disease and health*. International journal of biomedical science : IJBS, 2008. **4**(2): p. 89-96.

49. Xu, X., et al., *Differential expression and anti-oxidant function of glutathione peroxidase 3 in mouse uterus during decidualization*. FEBS Lett, 2014. **588**(9): p. 1580-9.
50. Agarwal, A., S. Gupta, and R.K. Sharma, *Role of oxidative stress in female reproduction*. Reproductive biology and endocrinology : RB&E, 2005. **3**: p. 28-28.
51. Adeoye, O., et al., *Review on the role of glutathione on oxidative stress and infertility*. JBRA assisted reproduction, 2018. **22**(1): p. 61-66.
52. Qiong, Z., et al., *Clinical validation of pinopode as a marker of endometrial receptivity: a randomized controlled trial*. Fertility and Sterility, 2017. **108**(3): p. 513-517.e2.
53. Quinn, K.E., et al., *Pinopodes: Recent advancements, current perspectives, and future directions*. Molecular and cellular endocrinology, 2020. **501**: p. 110644-110644.
54. Jin, X.Y., et al., *Pinopode score around the time of implantation is predictive of successful implantation following frozen embryo transfer in hormone replacement cycles*. Human Reproduction, 2017. **32**(12): p. 2394-2403.
55. D'Ippolito, S., et al., *Expression of Pinopodes in the Endometrium from Recurrent Pregnancy Loss Women. Role of Thrombomodulin and Ezrin*. Journal of clinical medicine, 2020. **9**(8): p. 2634.
56. Tamm-Rosenstein, K., et al., *Changes in the transcriptome of the human endometrial Ishikawa cancer cell line induced by estrogen, progesterone, tamoxifen, and mifepristone (RU486) as detected by RNA-sequencing*. PloS one, 2013. **8**(7): p. e68907-e68907.
57. Ullah, K., et al., *Serum estradiol levels in controlled ovarian stimulation directly affect the endometrium*. Journal of molecular endocrinology, 2017. **59**(2): p. 105-119.
58. Li, R., et al., *Mice endometrium receptivity in early pregnancy is impaired by maternal hyperinsulinemia*. Mol Med Rep, 2017. **15**(5): p. 2503-2510.
59. Campo, H., et al., *Microphysiological Modeling of the Human Endometrium*. Tissue engineering. Part A, 2020. **26**(13-14): p. 759-768.

TABLES

Table 1. Transcript ID and description, associated with differentially expressed transcripts between control, vehicle control, and Insulin treated groups. DEGs were identified following RNA sequencing of cells treated with control, vehicle control (acetic acid), or Insulin (2mg/mL) exposed endometrial epithelial (Ishikawa) cells cultured in a microfluidics device for 24 hr (n=3 biological replicates).

Control v Vehicle Control		Vehicle Control v Insulin	
Transcript	Description	Transcript	Description
MT-CYB	Mitochondrially encoded cytochrome B	SSB	Small RNA binding exonuclease protection factor La
MT-CO1	Mitochondrially encoded cytochrome C oxidase 1	SPCS1	Signal peptidase complex subunit 1
MT-CO2	Mitochondrially encoded cytochrome C oxidase 2	BTF3	Basic transcription factor 3
MT-ND3	Nicotinamide adenine dinucleotide + hydrogen (NADH)-Ubiquinone oxidoreductase Chain 3	GGCT	Gamma-glutamyl cyclotransferase
MT-ND5	NADH-Ubiquinone oxidoreductase chain 5	RPL7A	Ribosomal protein L7a
COA6	Cytochrome C oxidase assembly factor 6	RAPSN	Receptor associated protein of the synapse
ALPG	Alkaline phosphatase, germ cell	HTATSF1	HIV-1 Tat specific factor 1
THEGL	Theg spermatid protein like	TMSB10	Thymosin beta 10
HIST1H2BN	Histone H2B type 1-N	RPS6	Ribosomal protein S6
HMGA1	High mobility group AT-Hook 1		
SCX	Scleraxis BHLH transcription factor		
MKI67	Marker of proliferation Ki-67		
RPL36AL	Ribosomal protein L36A-like		
RPL19	Ribosomal protein L19		
PRKACA	Protein kinase cAMP-activated catalytic subunit alpha		
CTSZ	Cathepsin Z		
PPDPF	Pancreatic progenitor cell differentiation and proliferation factor		

<i>TCEAL4</i>	Transcription elongation factor A like 4		
<i>MT-ND1</i>	Mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 1		
<i>MT-ND4</i>	Mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 4		
<i>TMSB10</i>	Thymosin beta 10		
<i>RPS6</i>	Ribosomal protein S6		

Table 2. Gene Ontology terms involved in biological processes, cellular component, and molecular function associated with differentially expressed transcripts between control v vehicle control groups. Overrepresented GO terms and their descriptions associated with DEGs identified between control and vehicle exposed Ishikawa cells cultured in a microfluidics device for 24 hr (n=3 biological replicates). DEGs were identified following RNA sequencing of cells and overrepresentation analysis determined using Webgestelt.

	Gene ontology terms / GO ID	P-Value	FDR	Enrichment Score (-log ₁₀ [Pvalue])	Transcripts involved in biological function
Biological Processes	Mitochondrial electron transport, NADH to ubiquinone* (GO:0006120)	0.000026	0.0042	4.585	<i>MT-ND1</i> <i>MT-ND3</i> <i>MT-ND4</i> <i>MT-ND5</i>
	Mitochondrial respiratory chain complex I assembly* (GO:0032981)	0.000055	0.0045	4.260	<i>MT-ND1</i> <i>MT-ND3</i> <i>MT-ND4</i> <i>MT-ND5</i>
	ATP synthesis coupled electron transport* (GO:0042773)	0.0059	0.33	2.229	<i>MT-ND4</i> <i>MT-ND5</i>
	Response to hypoxia* (GO:0001666)	0.018	0.58	1.745	<i>MT-ND4</i> <i>MT-ND5</i> <i>MT-CYB</i>
	Response to copper ion* (GO:0046688)	0.018	0.58	1.745	<i>MT-CYB</i> <i>MT-CO1</i>
	Mitochondrial electron transport, cytochrome-c to oxygen* (GO:0006123)	0.024	0.65	1.620	<i>MT-CO1</i> <i>MT-CO2</i>
	Mesoderm formation* (GO:0001707)	0.033	0.74	1.481	<i>PRKACA</i> <i>SCX</i>
	Translation* (GO:0006412)	0.036	0.74	1.444	<i>RPL19</i> <i>RPL36AL</i> <i>RPS6</i>
	Cerebellum development* (GO:0021549)	0.043	0.79	1.367	<i>MT-ND4</i> <i>MT-CO1</i>
	Organ regeneration (GO:0031100)	0.055	0.85	1.260	<i>MT-CYB</i> <i>MKI67</i>

	Response to organic cyclic compound (GO:0014070)	0.057	0.85	1.244	<i>MT-ND1</i> <i>MKI67</i>
	Gene ontology terms	P value	FDR	Enrichment Score ($-\log_{10}[\text{Pvalue}]$)	Transcripts involved in cellular component
Cellular Component	Respiratory chain* (GO:0070469)	4.0E-9	2.5E-7	8.398	<i>MT-ND3</i> <i>MT-ND5</i> <i>MT-CYB</i> <i>MT-CO1</i> <i>MT-CO2</i>
	Mitochondrial inner membrane* (GO:0005743)	0.0000040	0.00012	5.398	<i>MT-ND1</i> <i>MT-ND3</i> <i>MT-ND4</i> <i>MT-ND5</i> <i>MT-CYB</i> <i>MT-CO1</i> <i>MT-CO2</i>
	Mitochondrial respiratory chain complex I* (GO:0005747)	0.000017	0.00035	4.770	<i>MT-ND1</i> <i>MT-ND3</i> <i>MT-ND4</i> <i>MT-ND5</i>
	Mitochondrion* (GO:0005739)	0.000029	0.00044	4.538	<i>MT-ND1</i> <i>MT-ND3</i> <i>MT-ND4</i> <i>MT-ND5</i> <i>MT-CYB</i> <i>COA6</i> <i>MT-CO1</i> <i>MT-CO2</i> <i>PRKACA</i>
	Respiratory chain complex IV* (GO:0045277)	0.0052	0.063	2.284	<i>MT-CO1</i> <i>MT-CO2</i>
	Membrane* (GO:0016020)	0.021	0.21	1.678	<i>MT-ND1</i> <i>MT-CYB</i> <i>MT-CO2</i> <i>MKI67</i> <i>PRKACA</i> <i>RPL19</i> <i>RPS6</i>
	Cytosolic large ribosomal subunit (GO:0022625)	0.069	0.60	1.161	<i>RPL19</i> <i>RPL36AL</i>

	Mitochondrial membrane (GO:0031966)	0.094	0.71	1.027	<i>MT-ND1</i> <i>MT-ND3</i>
	Gene ontology terms	P value	FDR	Enrichment Score ($-\log_{10}[\text{Pvalue}]$)	Transcripts involved in molecular function
Molecular Function	NADH dehydrogenase (ubiquinone) activity* (GO:0008137)	0.000020	0.00097	4.699	<i>MT-ND1</i> <i>MT-ND3</i> <i>MT-ND4</i> <i>MT-ND5</i>
	Cytochrome-c oxidase activity* (GO:0004129)	0.00051	0.012	3.292	<i>COA6</i> <i>MT-CO1</i> <i>MT-CO2</i>
	Structural constituent of ribosome* (GO:0003735)	0.025	0.33	1.602	<i>RPL19</i> <i>RPL36AL</i> <i>RPS6</i>
	Transcriptional activator activity, RNA polymerase II distal enhancer sequencer-specific binding* (GO:0003735)	0.028	0.33	1.553	<i>HMGA1</i> <i>SCX</i>
	Copper ion binding (GO:0005507)	0.061	0.59	1.215	<i>COA6</i> <i>MT-CO2</i>

*Marks statistical significance; $p \leq 0.05$, or FDR (False Discovery Rate) ≤ 0.05

Table 3. Overrepresented signalling pathways in DEGs between control v vehicle control groups. Overrepresented signalling pathways and their descriptions associated with DEGs identified between control and vehicle exposed Ishikawa cells cultured in a microfluidics device for 24 hr (n=3 biological replicates). DEGs were identified following RNA sequencing of cells and overrepresentation analysis determined using Webgestelt.

Gene set	Pathway Description	Gene set size	DEG overlap	P-value	FDR	Enrichment Ratio	Differentially expressed transcripts
hsa00730	Thiamine metabolism*	16	1	0.0175	0.7774	56.81	<i>ALPG</i>
hsa00790	Folate biosynthesis*	26	1	0.0283	0.7778	34.96	<i>ALPG</i>
hsa05020	Prion disease*	35	1	0.0379	0.7778	25.97	<i>PRKACA</i>
hsa03010	Ribosome*	134	3	0.0003	0.1044	20.35	<i>RPL19</i> <i>RPL36AL</i> <i>RPS6</i>
hsa04371	Apelin signalling pathway*	137	2	0.0092	0.7466	13.27	<i>PRKACA</i> <i>RPS6</i>
hsa04910	Insulin signalling pathway*	137	2	0.0092	0.7466	13.27	<i>PRKACA</i> <i>RPS6</i>
hsa04714	Thermogenesis*	229	3	0.0015	0.2503	11.91	<i>COA6</i> <i>PRKACA</i> <i>RPS6</i>
hsa05034	Alcoholism*	180	2	0.0155	0.7774	10.10	<i>HIST1H2BN</i> <i>PRKACA</i>
hsa05205	Proteoglycans in cancer*	198	2	0.0185	0.7774	9.181	<i>PRKACA</i> <i>RPS6</i>
hsa05203	Viral carcinogens*	201	2	0.0191	0.7774	9.044	<i>HIST1H2BN</i> <i>PRKACA</i>

*Marks statistical significance; $p \leq 0.05$, or FDR (False Discovery Rate) ≤ 0.05

Table 4. Gene Ontology terms involved in biological processes, cellular component, and molecular function associated with differentially expressed transcripts between vehicle

control v Insulin treated groups. Overrepresented GO terms and their descriptions associated with DEGs identified between vehicle and Insulin (2 mg/ml) exposed Ishikawa cells cultured in a microfluidics device for 24 hr (n=3 biological replicates). DEGs were identified following RNA sequencing of cells and overrepresentation analysis determined using Webgestelt.

	Gene ontology terms	P-Value	FDR	Enrichment Score ($-\log_{10}(\text{Pvalue})$)	Transcripts involved in biological function
Biological Function	SRP-dependent cotranslational protein targeting to membrane* (GO:0006614)	0.044	0.82	1.357	<i>RPL7A</i> <i>RPS6</i>
	Viral transcription (GO:0019083)	0.052	0.82	1.284	
	Nuclear-transcribed mRNA catabolic process, nonsense-mediated decay (GO:0000184)	0.055	0.82	1.260	
	Translational initiation (GO:0006413)	0.063	0.82	1.201	
	rRNA processing (GO:0006364)	0.098	0.99	1.009	
	Gene ontology terms	P-value	FDR	Enrichment Score ($-\log_{10}(\text{Pvalue})$)	Transcripts involved in cellular component
Cellular Component	Intracellular ribonucleoprotein complex (GO:1990904)	0.58	1.0	0.2366	<i>SSB</i> <i>RPS6</i>
	Ribosome (GO:0005840)	0.71	1.0	0.1487	<i>RPL7A</i> <i>RPS6</i>
	Gene ontology terms	P-value	FDR	Enrichment Score ($-\log_{10}(\text{Pvalue})$)	Transcripts involved in molecular function
Molecular Function	Poly(A) binding* (GO:0008143)	0.0011	0.021	2.959	<i>HTATSF1</i> <i>SSB</i> <i>BTF3</i> <i>RPL7A</i> <i>RPS6</i>
	RNA binding* (GO:0003723)	0.026	0.24	1.585	<i>HTATSF1</i> <i>SSB</i>

					<i>RPL7A</i>
--	--	--	--	--	--------------

*Marks statistical significance; $p \leq 0.05$, or FDR (False Discovery Rate) ≤ 0.05

Table 5. Overrepresented signalling pathways in DEGs between control v vehicle control groups. Overrepresented signalling pathways and their descriptions associated with DEGs identified between vehicle and Insulin (2mg/mL) exposed Ishikawa cells cultured in a microfluidics device for 24 hr (n=3 biological replicates). DEGs were identified following RNA sequencing of cells and overrepresentation analysis determined using Webgestelt.

Gene set	Pathway Description	Gene set size	DEG overlap	FDR	P-value	Enrichment Ratio	Differentially expressed transcripts involved
Hsa03060	Protein export*	23	1	1	0.0157	63.23	<i>SPCS1</i>
Hsa00480	Glutathione metabolism*	56	1	1	0.0379	25.97	<i>GGCT</i>
Hsa03010	Ribosome*	134	2	1	0.0033	21.70	<i>RPL7A</i> <i>RPS6</i>
Hsa01521	EGFR tyrosine kinase inhibitor resistance	79	1	1	0.0532	18.41	<i>RPS6</i>
Hsa04066	HIF-1 signalling pathway	100	1	1	0.0669	14.54	<i>RPS6</i>
Hsa05322	Systemic Lupus Erythematosus	133	1	1	0.0882	10.93	<i>SSB</i>
Hsa04371	Apelin signalling pathway	137	1	1	0.0908	10.62	<i>RPS6</i>
Hsa04910	Insulin signalling pathway	137	1	1	0.0908	10.62	<i>RPS6</i>
Hsa04150	mTOR signalling pathway	151	1	1	0.0996	9.631	<i>RPS6</i>
Hsa05205	Proteoglycans in cancer	198	1	1	0.1290	7.344	<i>RPS6</i>

*Marks statistical significance; $p \leq 0.05$, or FDR (False Discovery Rate) ≤ 0.05

FIGURES

Figure 1. Schematic diagram of experimental setup and work flow of experiment.

Diagrammatic representation of experimental approach using a microfluidics approach to mimic exposure to endometrial epithelial cells (n=3 biological replicates) to media control, vehicle control, or Insulin (2mg/mL) for 24 hr. Cells were analysed for a transcriptional response via RNA sequencing. Images produced with Biorender.

Figure 2. Venn diagram of DEGs identified in endometrial epithelial cells following exposure to control media, vehicle, or Insulin in a microfluidic device for 24 hrs. Ishikawa cells (n=3) were exposed to control medium, vehicle control (acetic acid: VC), or Insulin (2 mg/mL) for 24 hrs in a microfluidics device (1 ul/min). Following RNA sequencing DEGs in treatment groups were identified using a cut off of $p < 0.05$ and $\log_2\text{FoldChange} > 0$ or $\log_2\text{FoldChange} < 0$; fold change differences for transcripts were determined using paired t-tests. “Control v VC” demonstrates the transcripts altered when exposing Ishikawa cells to Control compared to those altered in VC. “VC v insulin” shows the comparison of DEGs expressed when Ishikawa cells were exposed to VC and insulin treatment. Results were found to be significant when $p < 0.05$, and the results were derived from n=3 biological replicates.

Figure 3. Over-representation analysis (ORA) graphs depicting enriched KEGG pathways associated DEGs found in Control v Vehicle Control groups. ORA was produced by Webgestalt with the gene identifier “Gene Symbol” and functional database of “KEGG pathways”. Benjamini-Hochberg method was used to adjust P-values and presented as FDR, $FDR \leq 0.05$ being the threshold for statistical significance. A) Bar chart illustrates enrichment ratio plotted against enriched pathway identified through ORA, with the blue-colour shade indicating statistical significance based on FDR (dark blue = $FDR \leq 0.05$; light blue = $FDR > 0.05$). The chart is organised according to decreasing enrichment ratio, with the top pathway being most enriched and bottom being least enriched. B) Volcano plot plotting $-\log_{10}$ of FDR against $\log_2$ of enrichment ratio for each pathway. Darker purple shade of plotted dots indicates pathway of interest, as it demonstrates notable magnitude in both $\log_2$ of enrichment ratio and $-\log_{10}$ of FDR compared to other regulatory networks.

Figure 4. Over-representation analysis (ORA) graphs depicting enriched KEGG pathways associated DEGs found in Vehicle Control v Insulin treated cells. ORA were produced by Webgestalt with the gene identifier “Gene Symbol” and functional database of “KEGG pathways”. Benjamini-Hochberg method was used to adjust P-values and presented as FDR, $FDR \leq 0.05$ being the threshold for statistical significance. A) Bar chart illustrates enrichment ratio plotted against enriched pathway identified through ORA, with the blue-colour shade indicating statistical significance based on FDR (dark blue = $FDR \leq 0.05$; light blue = $FDR > 0.05$). The chart is organised according to decreasing enrichment ratio, with the top pathway being most enriched and bottom being least enriched. B) Volcano plot plotting $-\log_{10}$ of FDR against $\log_2$ of enrichment ratio for each pathway. Darker purple shade of plotted dots indicates pathway of interest, as it demonstrates notable magnitude in both $\log_2$ of enrichment ratio and $-\log_{10}$ of FDR compared to other regulatory networks.

Figure 5. Over-representation analysis (ORA) graphs depicting enriched KEGG pathways associated DEGs found in Vehicle Control v Insulin groups. ORA were produced by Webgestalt with the gene identifier “Gene Symbol” and functional database of “KEGG pathways”. Benjamini-Hochberg method was used to adjust P-values and presented as FDR, $FDR \leq 0.05$ being the threshold for statistical significance. A) Bar chart illustrates enrichment ratio plotted against enriched pathway identified through ORA, with the blue-colour shade indicating statistical significance based on FDR (dark blue = $FDR \leq 0.05$; light blue = $FDR > 0.05$). The chart is organised according to decreasing enrichment ratio, with the top pathway being most enriched and bottom being least enriched. B) Volcano plot plotting $-\log_{10}$ of FDR against $\log_2$ of enrichment ratio for each pathway. Darker purple shade of plotted dots indicates pathway of interest, as it demonstrates notable magnitude in both $\log_2$ of enrichment ratio and $-\log_{10}$ of FDR compared to other regulatory networks.

Figure 6. Bar charts indicating overrepresented GO terms for biological processes, cellular component, and molecular functions associated with DEGs. Charts are divided into two groups: A) biological processes, B) cellular component, and C) molecular function for n=22 DEGs involved in Control v. VC group, and D, E, and F depicting gene ontology terms found in from n=9 DEGs involved in VC v. Insulin group. All DEGs involved in GO terms in A), B) and C) were upregulated, thus shown in orange. All DEGs involved in the GO terms in D), E), and F) were downregulated as RAPSIN (the only upregulated DEG out of n=9 DEGs in VC v Insulin) was not associated with any of the functional annotations, thus shown in blue. GO terms and p-values were determined by overrepresented functional annotation analysis using DAVID. P-values were used to calculate enrichment scores ($-\log_{10}[\text{Pvalue}]$). Colour gradient depicts size of enrichment score, darker being more enriched (or having higher p-value), and lighter being less enriched.

Figure 7. Proposed mechanism by which insulin alters endometrial function. Created using Biorender.